Rebecca Whiting

Dr. Rebecca Whiting


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Experimental Eye Research
Verified
Journal Article
Open access
RWRebecca Whiting
Rebecca Whiting
CJCheryl A. Jensen
Cheryl A. Jensen
JPJacqueline W. Pearce
Jacqueline W. Pearce
LGLauren E. Gillespie
Lauren E. Gillespie
DBDaniel E. Bristow
Daniel E. Bristow
MKMartin L. Katz
Martin L. Katz
CLN2 disease is one of a group of lysosomal storage disorders called the neuronal ceroid lipofuscinoses (NCLs). The disease results from mutations in the TPP1 gene that cause an insufficiency or complete lack of the soluble lysosomal enzyme tripeptidyl peptidase-1 (TPP1). TPP1 is involved in lysosomal protein degradation, and lack of this enzyme results in the accumulation of protein-rich autofluorescent lysosomal storage bodies in numerous cell types including neurons throughout the central nervous system and the retina. CLN2 disease is characterized primarily by progressive loss of neurological functions and vision as well as generalized neurodegeneration and retinal degeneration. In children the progressive loss of neurological functions typically results in death by the early teenage years. A Dachshund model of CLN2 disease with a null mutation in TPP1 closely recapitulates the human disorder with a progression from disease onset at approximately 4 months of age to end-stage at 10-11 months. Delivery of functional TPP1 to the cerebrospinal fluid (CSF), either by periodic infusion of the recombinant protein or by a single administration of a TPP1 gene therapy vector to the CSF, significantly delays the onset and progression of neurological signs and prolongs life span but does not prevent the loss of vision or modest retinal degeneration that occurs by 11 months of age. In this study we found that in dogs that received the CSF gene therapy treatment, the degeneration of the retina and loss of retinal function continued to progress during the prolonged life spans of the treated dogs. Eventually the normal cell layers of the retina almost completely disappeared. An exception was the ganglion cell layer. In affected dogs that received TPP1 gene therapy to the CSF and survived an average of 80 weeks, ganglion cell axons were present in numbers comparable to those of normal Dachshunds of similar age. The selective preservation of the retinal ganglion cells suggests that while TPP1 protein delivered via the CSF may protect these cells, preservation of the remainder of the retina will require delivery of normal TPP1 more directly to the retina, probably via the vitreous body.

1 November 2016 in Experimental Eye Research
Verified
Journal Article
Open access
CTChristopher J. Tracy
Christopher J. Tracy
RWRebecca Whiting
Rebecca Whiting
JPJacqueline W. Pearce
Jacqueline W. Pearce
BWBaye G. Williamson
Baye G. Williamson
DVDaniella P. Vansteenkiste
Daniella P. Vansteenkiste
MKMartin L. Katz
Martin L. Katz
The CLN2 form of neuronal ceroid lipofuscinosis is a neurodegenerative disease that results from mutations in the TPP1 gene. Affected children exhibit progressive declines in most neurological functions including vision. Functional declines are accompanied by progressive brain and retinal atrophy. TPP1 encodes the soluble lysosomal enzyme tripeptidyl peptidase-1 (TPP1). Dachshunds with a TPP1 null mutation exhibit a disorder very similar to human CLN2 disease. Periodic infusion of recombinant TPP1 protein or a single injection of a TPP1 gene therapy vector into the cerebrospinal fluid of affected dogs significantly delays the onset and progression of neurological signs but does not slow vision loss or retinal degeneration. Studies were conducted to determine whether intravitreal implantation of autologous bone marrow derived stem cells transduced with a TPP1 expression construct would inhibit retinal degeneration in the canine model. A single injection of the transduced cells at an early stage in the disease progression substantially inhibited the development of disease-related retinal function deficits and structural changes. No adverse effects of the treatment were detected. These findings indicate that ex vivo gene therapy using autologous stem cells is an effective means of achieving sustained delivery of therapeutic compounds to tissues such as the retina for which systemic administration would be ineffective.

15 April 2026 in Genes
Verified
Journal Article
Open access
PDF file
JCJoan Ripley Coates
Joan Ripley Coates
KKKristen Keyes
Kristen Keyes
RWRebecca Whiting
Rebecca Whiting
JOJuri Ota-Kuroki
Juri Ota-Kuroki
BMBrandie Morgan-Jack
Brandie Morgan-Jack
MKMartin L. Katz
Martin L. Katz
Background/Objectives: Among the most common hereditary neurodegenerative disorders in people are the neuronal ceroid lipofuscinoses (NCLs), a subgroup of lysosomal storage disorders. For most cases of NCL, the genes containing the causative variants have been identified. NCLs also occur in dogs, and in most instances variants responsible for the canine NCLs occur in genes orthologous to those associated with the human disorders. An adult miniature Dachshund presented with clinical signs consistent with NCL. Studies were undertaken to determine whether the disease phenotype supported the classification of the disease as an NCL and to identify potential causal DNA sequence variants. Methods: The proband underwent complete neurological and ophthalmological examinations followed by euthanasia. Tissues were examined for NCL-like pathology. Whole genome sequence analysis (WGS) was performed. Results: The clinical signs and tissue pathology were consistent with those of NCL disease, although with some features distinct from previously described forms of canine NCL. The proband was uniquely homozygous for variants in five genes associated with lysosomal function, four of which have not previously been associated with the NCLs. Conclusions: The proband suffered from a novel NCL-like disorder. Determining whether one or a combination of more than one of the five potentially causal DNA sequence variants was responsible for the disease will require evaluation of additional cases.

2 October 2026 in Biology
Verified
Journal Article
Open access
PDF file
BMBrandie Morgan-Jack
Brandie Morgan-Jack
GKGrace Kick
Grace Kick
ZLZhen Lyu
Zhen Lyu
TJTrupti Joshi
Trupti Joshi
BMBrian Mooney
Brian Mooney
RWRebecca Whiting
Rebecca Whiting
CLN2 disease is a fatal lysosomal storage disorder caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1), resulting in progressive neurodegeneration and non-neuronal pathology. While enzyme replacement therapy has improved disease management, there remains a critical need for objective molecular biomarkers capable of monitoring disease progression and therapeutic response. The purpose of this study was to utilize a canine model of CLN2 disease to investigate proteomic changes in cerebrospinal fluid (CSF) and in minimally invasive biofluids tears and plasma to identify candidate disease biomarkers. Untargeted proteomic analysis was conducted using these biofluids from unaffected controls and CLN2-affected dogs at presymptomatic, symptomatic, and advanced disease stages. CSF demonstrated the greatest degree of proteomic alterations over the disease progression. Proteins associated with cytoskeletal organization, synaptic signaling, lysosomal biology, mitochondrial metabolism, lipid homeostasis, and inflammatory responses were significantly altered. Tear fluid demonstrated overlapping biological themes with CSF, particularly involving mitochondrial metabolism, lysosomal function, and lipid-associated pathways. In contrast, plasma proteomic alterations were comparatively modest but supported systemic changes associated with extracellular signaling, inflammation, and lipid metabolism. Collectively, these findings demonstrate progressive and coordinated proteomic alterations across multiple biofluids in CLN2 disease that can serve as candidate biomarkers of disease progression.

2 April 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JCJoan Ripley Coates
Joan Ripley Coates
KKKristen Keyes
Kristen Keyes
RWRebecca Whiting
Rebecca Whiting
JOJuri Ota-Kuroki
Juri Ota-Kuroki
BMBrandie Morgan-Jack
Brandie Morgan-Jack
MKMartin L. Katz
Martin L. Katz
Background/Objectives: Among the most common hereditary neurodegenerative disorders in people are the neuronal ceroid lipofuscinoses (NCLs), a subgroup of lysosomal storage disorders. For most cases of NCL, the genes containing the causative variants have been identified. NCLs also occur in dogs, and in most instances variants responsible for the canine NCLs occur in genes orthologous to those associated with the human disorders. An adult Miniature Dachshund presented with clinical signs consistent with NCL. Studies were undertaken to determine whether the disease phenotype supported classification of the disease as an NCL and to identify potential causal DNA sequence variants. Methods: The proband underwent complete neurologic and ophthalmological examinations followed by euthanasia. Tissues were examined for NCL-like pathology. Whole genome sequence analysis (WGS) was performed. Results: The clinical signs and tissue pathology were consistent with those of NCL disease, although with some features distinct from previously described forms of canine NCL. The proband was uniquely homozygous for variants in 5 genes associated with lysosomal function, 4 of which have not previously been associated with the NCLs. Conclusion: The proband suffered from a novel NCL-like disorder. Determining whether one or a combination of more than one of the 5 potentially causal DNA sequence variants was responsible for the disease will require evaluation of additional cases.